We report a case of alopecia associated with alemtuzumab treatment for MS, the third case described in the literature, to our knowledge.^[@R1],[@R2]^ A 31-year-old woman diagnosed with relapsing-remitting MS in February 2015 presented with demyelinating lesions in the medulla, cerebellar peduncle, cerebellar hemisphere in addition to \>9 T2 supratentorial lesions on brain MRI. She was treated with an MS disease-modifying therapy (dimethyl fumarate 240 mg twice a day) for 8 months and experienced 2 clinical relapses during this time, prompting escalation to treatment with alemtuzumab (60 mg) in June 2016. Her second course of treatment with alemtuzumab (36 mg) occurred in June 2017, with lymphocyte count reaching 0.5 × 10^9^/L 30 days posttreatment. Following alemtuzumab treatment, the patient was healthy without clinical or radiologic MS disease activity and had no other medical concerns. Two months after second course of treatment with alemtuzumab, the patient had a lymphocyte count of 0.7 × 10^9^/L and experienced significant patchy hair loss, and a dermatologist confirmed the diagnosis of alopecia areata (AA). Hair loss continued over a period of 5 months, during which her lymphocyte count ranged from 0.7 to 0.8 × 10^9^/L. She had a positive hair pull test, indicating further hair loss, despite treatment with intralesional scalp injections of triamcinolone acetonide (5 mg/cc, 3 cc total) in most of the affected areas both on AA diagnosis and 1 month later. Six months after the second course of alemtuzumab, the patient experienced a sensory partial transverse myelitis relapse, which was acutely managed with intravenous methylprednisolone 1,000 mg for 5 days. Within 4 weeks after her systemic steroid treatment, hair regrowth including regions of depigmentation was noted. The patient\'s lymphocyte count during this time was 0.9 × 10^9^/L. Within 4 months of steroid treatment, hair regrowth was present over the entire scalp ([figure](#F1){ref-type="fig"}).

![Alopecia areata hair regrowth after systemic corticosteroid treatment](NEURIMMINFL2018017616f1){#F1}

Discussion {#s1}
==========

Alemtuzumab is a monoclonal antibody that targets CD52 causing T- and B-lymphocyte depletion. It is known to cause secondary autoimmunity, including thyroid disease, immune thrombocytopenic purpura, and anti-glomerular basement membrane disease. Proposed mechanisms of secondary autoimmunity with alemtuzumab include the initial induction of lymphopenia and (1) the subsequent propagation of self-antigen responsive T cells that escaped depletion in conjunction with an increased probability of T cells encountering self-antigen and/or (2) the subsequent hyperrepopulation of B cells causing secondary B-cell autoimmunity.^[@R3]^ Although secondary autoimmune diseases have previously been reported with various rates of occurrence, AA has been rare and only briefly described.^[@R4]^ One report of untreated alopecia universalis following alemtuzumab treatment in an MS patient demonstrated no improvement after a 6-months follow-up period to which the patient declined further treatments for alopecia.^[@R2]^ A second report of alopecia universalis associated with alemtuzumab in MS documented complete hair regrowth 2 years after the last alemtuzumab infusion despite no treatment for alopecia.^[@R1]^

AA is an autoimmune disease that can involve focal or multifocal patches of nonscarring hair loss and is believed to be caused by CD4^+^ T lymphocytes attacking the hair follicle.^[@R5]^ This infiltration of lymphocytes causes the follicle keratinocytes to undergo apoptosis and stop the production of hair.^[@R5]^ AA can be treated with topical immunotherapy, intralesional scalp corticosteroids, or systemic corticosteroids (either oral or intravenous). Patients with shorter AA disease duration and less severe involvement respond well to systemic corticosteroids with higher remission rates using a common dose of 500 mg methylprednisolone intravenous for 3 days with minimal side effects.^[@R6]^ Due to the autoimmune pathogenesis of AA, the immunosuppression and anti-inflammatory properties of corticosteroids can be effective.

This third case of alemtuzumab-associated alopecia shows a temporal connection with the development of an autoimmune disease similar to the other 2 cases noted. In contrast to those other cases, our patient experienced significant and rapid hair regrowth after IV methylprednisolone treatment for an acute MS relapse. Although spontaneous hair regrowth occurs in 30%--50% of patients with AA within the first year, it may be possible to expedite this process with the use of systemic methylprednisolone.^[@R7]^ Indeed, systemic corticosteroids have been successfully used to treat AA in patients who have not received alemtuzumab exposure.^[@R7]^ We show that systemic corticosteroids can also be considered as a treatment for alemtuzumab-related AA. Long-term follow-up of our patient is needed to determine the extent of hair regrowth and any risk of alopecia recurrence.

AA is a rare secondary autoimmune complication of alemtuzumab treatment for MS. As such, systemic corticosteroids may be an effective treatment to promote hair regrowth in patients experiencing this complication.
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